Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Paul Nguyen is an internationally-recognized expert in prostate cancer clinical care and research. He has published over 250 original research articles and has national leadership as the vice-chair of the ARS/ACR Appropriateness Criteria Committee for Prostate Cancer and Chair of the Program Committee for the 2019 ASTRO/SUO/ASCO Genitourinary Cancers Symposium. He is the Principal Investigator of the multi-center randomized FORMULA-509 trial and co-chair of the international randomized ENZARAD trial. He serves as the DF/BWCC Genitourinary Clinical Center Director for Radiation Oncology, Vice-Chair for Clinical Research in the Department of Radiation Oncology, and Associate Professor at Harvard Medical School. He received his AB from Harvard College, MD from Harvard Medical School, and completed his residency at the Harvard Radiation Oncology Program where he served as chief resident.
Dr. Nguyen’s primary research expertise is the optimal use of systemic therapy with radiation for high-risk prostate cancer, side effects of androgen-deprivation therapy, and the genetic and molecular markers to optimize risk stratification and personalization of treatment for men with prostate cancer. In addition he has published extensively in health services research and racial disparities in prostate cancer treatment and outcome.
Brigham and Women's Hospital75 Francis StreetBoston, MA 02215Get Directions